Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, randomized, 2-sequence, multiple-dose, cross-over study to investigate the drug-drug interaction of Sevikar and Crestor in healthy adult volunteers

Trial Profile

An open label, randomized, 2-sequence, multiple-dose, cross-over study to investigate the drug-drug interaction of Sevikar and Crestor in healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Rosuvastatin (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertension; Hypertriglyceridaemia
  • Focus Pharmacokinetics
  • Sponsors Daewoong Pharmaceutical
  • Most Recent Events

    • 28 Apr 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2014 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea: KCT0001058).
    • 25 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top